Investigational drug · Phase 2
silevertinib
Also called: BDTX-1535
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "silevertinib"
First trial start
2022
Mar 31, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "silevertinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Glioblastoma (GBM)
- Newly Diagnosed Glioblastoma
- GBM
- Glioblastoma Multiforme (GBM)
- Glioma
- Central Nervous System Diseases
- Brain Cancer
- Non-Small Cell Lung Cancer
- Advanced Non-Small Cell Squamous Lung Cancer
- Metastatic Lung Non-Small Cell Carcinoma
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Brain tumors (glioma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "silevertinib" as an intervention, largest first.
Black Diamond Therapeutics, Inc.Industry
NCT05256290 · 220 participants (planned) · Start Mar 31, 2022 · Primary completion Mar 2028
Drug: silevertinib monotherapy · For: Non-Small Cell Lung Cancer; Advanced Non-Small Cell Squamous Lung Cancer; Metastatic Lung Non-Small Cell Carcinoma and 7 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Irvine, California · 19 sites in all
- Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIPivotal-lookingRecruiting
Black Diamond Therapeutics, Inc.Industry
NCT07326566 · 162 participants (planned) · Start May 5, 2026 · Primary completion Nov 2028
Drug: silevertinib in combination with temozolomide; temozolomide (TMZ) · For: Glioblastoma (GBM); Newly Diagnosed Glioblastoma; GBM and 4 more
Sites: Birmingham, Alabama; Springdale, Arkansas; La Jolla, California · 39 sites in all
St. Joseph's Hospital and Medical Center, PhoenixAcademic, hospital or other
NCT06072586 · 82 participants (planned) · Start Oct 18, 2023 · Primary completion Dec 2027
Drug: BDTX-1535; BDTX-1535 combined with radiation therapy and 1 more · For: High Grade Glioma; Glioblastoma
Sites: Chandler, Arizona; Phoenix, Arizona
Newest research
PubMed records naming it or its code names, newest first.
- Recent advances in synthetic strategies of fourth-generation EGFR tyrosine kinase inhibitors under clinical trials for the treatment of resistant non-small cell lung cancer (NSCLC).
Kadam VM, Patel HM · Bioorg Chem 2026
- Comparative profiling of osimertinib and fourth-generation EGFR inhibitors on EGFR-mutant proteins and cell lines.
Melis JJTM, Kevenaar KJW, Ytsma J, et al. · Front Oncol 2026
- Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024).
Nagpure NR, Patel HM · Expert Opin Ther Pat 2025
- A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Gawli CS, Patil CR, Patel HM · Bioorg Med Chem 2025
- Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-review.
Dempke WCM, Fenchel K · Transl Cancer Res 2024
- BDTX-1535 Goes after Osimertinib Resistance.
· Cancer Discov 2021
Also in development for Glioblastoma (GBM)
- BreakVaxPhase 22 trials
BreakBio Corp · Triple-Negative Breast Cancer (TNBC), Glioblastoma (GBM)
- DOC1021Phase 22 trials
Diakonos Oncology Corporation · Glioblastoma (GBM), Refractory Melanoma
- MT-125Phase 22 trials
Myosin Therapeutics Inc. · Glioblastoma (GBM), Glioblastoma
- JBI-778Phase 21 trial
Jubilant Therapeutics Inc. · Brain Metastases From Solid Tumors, Leptomeningeal Disease, High Grade Glioma (HGG)
- TGX-007Phase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
- ValaciclovirPhase 21 trial
Trogenix ltd · Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.